XML 55 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
ACQUISITIONS - Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Oct. 19, 2015
USD ($)
Oct. 01, 2015
USD ($)
Apr. 01, 2015
USD ($)
product
$ / shares
Feb. 23, 2015
USD ($)
Sep. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
Oct. 31, 2015
USD ($)
Feb. 10, 2015
USD ($)
Business Acquisition [Line Items]                          
Acquisition-related contingent consideration         $ 87,300,000   $ 196,800,000   $ 87,300,000   $ 196,800,000    
Acquisition of businesses, contingent and deferred consideration obligations at fair value                 0 $ 744,500,000      
Purchase price net of cash received                 18,500,000 14,001,700,000      
Pro forma acquisition accounting adjustment on inventory sold subsequent to acquisition date               $ 25,000,000   $ 94,000,000      
Amoun                          
Business Acquisition [Line Items]                          
Total fair value of consideration transferred $ 906,000,000                        
Acquisition of noncontrolling interest 847,000,000                        
Acquisition-related contingent consideration 75,000,000                        
Acquisition of businesses, contingent and deferred consideration obligations at fair value $ 59,000,000                        
Aggregate purchase price         906,400,000       906,400,000        
Sprout Pharmaceuticals, Inc.                          
Business Acquisition [Line Items]                          
Total fair value of consideration transferred   $ 530,000,000       $ 500,000,000              
Acquisition-related contingent consideration   422,000,000                      
Acquisition of businesses, contingent and deferred consideration obligations at fair value           $ 495,000,000              
Purchase price   1,450,000,000                      
Commencement trigger, sales revenue   1,000,000,000                      
Aggregate purchase price   1,446,500,000                      
Salix                          
Business Acquisition [Line Items]                          
Total fair value of consideration transferred     $ 13,132,000,000                    
Number of products in product portfolio (more than) | product     20                    
Par value per share of common stock (in dollars per share) | $ / shares     $ 0.001                    
Per share consideration (in usd per share) | $ / shares     $ 173.00                    
Aggregate purchase price             13,132,000,000       13,132,000,000    
Range of potential milestone payment, high     $ 650,000,000                    
Salix | Restricted Stock                          
Business Acquisition [Line Items]                          
Per share consideration (in usd per share) | $ / shares     $ 173.00                    
Other 2015 Acquisitions                          
Business Acquisition [Line Items]                          
Total fair value of consideration transferred                     1,410,000,000    
Acquisition of businesses, contingent and deferred consideration obligations at fair value                     186,000,000    
Aggregate purchase price         1,406,800,000       1,406,800,000        
Dendreon                          
Business Acquisition [Line Items]                          
Acquisition of noncontrolling interest       $ 495,000,000                  
Purchase price net of cash received       415,000,000                  
Cash received from acquisition       80,000,000                  
Stock consideration transferred       $ 50,000,000                  
Marathon                          
Business Acquisition [Line Items]                          
Purchase price net of cash received         5,000,000       32,000,000   35,000,000    
Aggregate purchase price                         $ 286,000,000
Assumed liability owed to a third party                         $ 64,000,000
Range of potential milestone payment, high             200,000,000       $ 200,000,000    
Brodalumab                          
Business Acquisition [Line Items]                          
Upfront payment                       $ 100,000,000  
Brodalumab | Pre-launch Milestone Payments                          
Business Acquisition [Line Items]                          
Range of potential milestone payment, high   170,000,000     $ 150,000,000       $ 150,000,000        
Brodalumab | Sales Based Milestone Payments                          
Business Acquisition [Line Items]                          
Range of potential milestone payment, high   175,000,000                      
Other (Income) Expense | Amoun                          
Business Acquisition [Line Items]                          
Payments to employees             $ 12,000,000            
Minimum | Sprout Pharmaceuticals, Inc.                          
Business Acquisition [Line Items]                          
Purchase obligation   $ 200,000,000